The private equity firms, Arcadia Sgr spa (“Arcadia”) – through its fund Arcadia Small Cap I – and Futurimpresa Sgr spa (“Futurimpresa”) – through its fund Finanza e Sviluppo Impresa – (together with Arcadia, the “Funds”) have acquired Lisapharma from the Zagnoli family. Lisapharma, based in Erba (Como) operates in the pharmaceutical market as a manufacturer of sterile injectable drugs both for proprietary brands and as contractor for third parties. The deal was completed by acquiring 100% of the capital in an all equity structure. The new shareholders are Arcadia with a majority stake of 53.7%, Futurimpresa with the 44.3%, Giovanni Franchi and Massimiliano Delfrate, respectively President and CEO, with the remaining 2%. The transaction was originated by Arcadia and executed by Nino Dell’Arte and Francesca Fontana, on Arcadia’s side, and Luigi Glarey, CEO, and Massimo Imperiali for Futurimpresa.
The acquisition of Lisapharma represents the fourth investment for Arcadia Small Cap I which focuses on small medium companies. The fund is managed by Arcadia Sgr spa, an independent asset management company founded by Guido Belli and Simone Arnaboldi. Simone Arnaboldi, the CEO, declares :”after the investments in VSP fasteners, Vision group and h-old, with the completion of Lisapharma, Arcadia Small Cap I has now deployed the 70% of its commitments by acquiring profitable companies with solid prospects of grow